US Patent 8,945,612: Claim Scope, Inbrija Patent Landscape and Generic Entry Risk

US Patent 8,945,612 covers a low-density levodopa dry-powder capsule designed for use in an inhalation device. Its central limitation is not levodopa alone. Infringement requires the combination of a specified powder composition, low working density, HPMC capsule shell containing titanium dioxide, and superior powder emission compared with an HPMC capsule without titanium dioxide.[1]

The patent is directed to the capsule-and-powder delivery system associated with inhaled levodopa products, particularly Acorda Therapeutics' Inbrija, whose active ingredient is levodopa and whose FDA-approved product uses a single-dose inhalation device and capsules containing inhalation powder.[2]

What does US Patent 8,945,612 protect?

The independent claim protects a combination of five technical elements:

Claim element	Required limitation
Dosage form	Capsule for use in an inhalation device
Active ingredient	Dry powder comprising levodopa
Excipients	A salt and a phospholipid
Powder density	Working density of approximately 0.02 to 0.1 g/cm³
Capsule shell	HPMC containing titanium dioxide
Performance	Greater levodopa powder emission than an HPMC capsule without titanium dioxide
Composition	Approximately 80% to 95% levodopa

The claim is narrower than a general inhaled-levodopa claim. A competing product would need to satisfy the claimed capsule shell, composition, density and performance limitations together.

What is the inventive center of the patent?

The practical inventive center is the use of titanium dioxide in an HPMC capsule to improve powder discharge during actuation of an inhaler. The claim does not merely require a white or opaque capsule. It requires:

An HPMC shell.
Titanium dioxide in that shell.
A comparative emission result showing more powder release than from an HPMC shell without titanium dioxide.

This performance limitation gives the claim a functional character. Testing would likely compare otherwise similar capsules under defined inhaler-actuation conditions.

The patent therefore combines formulation protection with device-performance protection. A competitor may avoid some composition limitations yet still face risk if it uses the claimed capsule architecture and obtains the claimed emission result.

How do claims 2 through 14 narrow the patent?

The dependent claims create multiple infringement positions around density, moisture, dose, capsule size and excipient identity.

Claim	Added limitation	Commercial significance
2	Working density of 0.02 to 0.05 g/cm³	Covers the lower-density portion of claim 1
3	Water content of 2% to 8% by weight	Targets moisture-controlled powder
4	Water content of 5% to 6%	Narrow formulation range
5	Size 00 capsule	Matches a common inhalation capsule format
6	15 to 50 mg levodopa	Covers therapeutic dose range
7	25 to 35 mg levodopa	Narrower commercial dose range
8	Sodium chloride as the salt	Narrows the salt component
9	DPPC as the phospholipid	Narrows the phospholipid component
10	85% to 95% levodopa	High-drug-load formulation
11	Fine-particle fraction of 50% to 70% of nominal dose	Adds aerodynamic performance
12	At least approximately 20 mg dry powder	Minimum fill weight
13	30 to 50 mg dry powder	Commercial fill-weight range
14	Sodium chloride and DPPC together	Narrow combination claim

Claims 9 and 14 are especially important because DPPC and sodium chloride are common formulation components in inhaled-levodopa development programs. A product using both could face a more concentrated claim set than a formulation using an alternative phospholipid or salt.

What are the key claim-construction issues?

How should “working density” be interpreted?

“Working density” is a critical limitation. It is generally understood as the density of the powder in the filled capsule under the relevant handling or filling condition, rather than the true particle density of crystalline levodopa.

A challenger could argue that the patent does not define the measurement method with sufficient precision. The patentee would likely respond that the specification provides the relevant test conditions and that a skilled person would understand the term in the context of inhalation powder manufacture.

Because the claimed range is broad, a product with a measured working density of 0.03 g/cm³ would fall within both claim 1 and claim 2. A product at 0.08 g/cm³ would fall within claim 1 but not claim 2.

What does “emits more powder” require?

The emission limitation requires a comparison against an HPMC capsule without titanium dioxide. Important variables include:

Inhaler model.
Capsule size and geometry.
Capsule wall thickness.
Powder fill weight.
Storage humidity.
Actuation pressure and duration.
Number of actuations.
Measurement endpoint.

The claim does not specify a percentage improvement. It appears to require a relative increase, not a minimum numerical threshold. This creates potential enablement, indefiniteness and reproducibility issues if the specification does not establish a standardized comparison protocol.

The limitation may also complicate infringement litigation. A patentee would need reliable testing showing that the accused capsule emits more powder under a legally relevant comparison.

Does “capsule comprises 80% to 95% levodopa” apply to the shell or powder?

In context, the limitation is most naturally read as applying to the dry powder contained in the capsule, not the HPMC shell. Claim 10 expressly states that “the dry powder comprises” 85% to 95% levodopa, supporting that interpretation.

The claim language still creates a potential drafting ambiguity because claim 1 initially states that the capsule is filled with a powder and later says that “the capsule comprises” 80% to 95% levodopa. A court would likely construe the limitation in light of the specification and dependent claims.

What formulations are protected by US 8,945,612?

The strongest formulation position is represented by claims 9 and 14:

Levodopa.
Sodium chloride.
DPPC.
High levodopa loading.
Low working density.
Controlled moisture.
HPMC capsule shell with titanium dioxide.

The patent does not require every dependent limitation simultaneously. A product using levodopa, sodium chloride and DPPC may fall within claim 14 only if it also satisfies all limitations inherited from claim 1, including the capsule material, titanium dioxide, density and emission comparison.

What is the role of DPPC?

Dipalmitoylphosphatidylcholine, or DPPC, is a phospholipid that can affect powder dispersibility, particle interaction and aerosol performance. Claim 9 narrows the generic “phospholipid” limitation to DPPC. Claim 14 combines DPPC with sodium chloride.

A formulation using a different phospholipid, such as phosphatidylcholine with a different fatty-acid composition, may avoid literal infringement of claims 9 and 14 while remaining exposed under claim 1 if it satisfies the broader phospholipid limitation.

What is the role of sodium chloride?

Sodium chloride is expressly claimed in claims 8 and 14. It may function as a formulation excipient affecting powder structure, dispersion and delivered dose. A substitute salt could avoid those dependent claims but would not necessarily avoid claim 1, which broadly recites “a salt.”

How strong is the patent estate for inhaled levodopa?

US 8,945,612 is a targeted but commercially relevant patent. Its strength is strongest where the accused product uses the same capsule technology and a similar powder platform. Its principal limitations are the comparative emission requirement and the need to prove the claimed working-density range.

Strength factor	Assessment
Product relevance	High for capsule-based inhaled levodopa
Composition coverage	Moderate to high
Capsule-shell coverage	High where HPMC and titanium dioxide are used
Dose coverage	Strong for 20 to 50 mg powder fills and 25 to 35 mg levodopa doses
Performance limitation	Potentially difficult to test and prove
Design-around potential	Moderate
Biosimilar relevance	Low; product is a small-molecule drug
Orange Book relevance	Potentially significant if listed for the approved product
Manufacturing relevance	High where the same low-density powder and capsule process are used

The patent does not cover all inhaled levodopa products. A non-capsule inhaler, a blister-based system, a formulation outside the density range, or a shell material other than HPMC could reduce exposure.

What is the patent expiration timeline?

US 8,945,612 issued on February 3, 2015.[1] The enforceable term is calculated from the earliest effective nonprovisional filing date in the patent family, subject to patent-term adjustment and any applicable regulatory extension.

The patent is associated with the Civitas Therapeutics inhaled-levodopa technology later commercialized by Acorda Therapeutics. The relevant commercial product is Inbrija, FDA-approved in 2018.[2] A standard 20-year term for the relevant patent family would place expiration around the early 2030s, subject to the official USPTO term calculation and any patent-term adjustment.

Milestone	Date or period
US patent issued	February 3, 2015
Inbrija FDA approval	December 21, 2018
Standard patent-term framework	20 years from earliest effective nonprovisional filing
Expected term window	Early 2030s
Regulatory exclusivity	Separate from patent term and product-specific
Patent-term extension	Must be determined from the official patent and FDA records

Patent expiration and FDA exclusivity are separate. Loss of patent protection does not necessarily eliminate regulatory exclusivity, and expiration of regulatory exclusivity does not terminate an unexpired patent.

What is the Orange Book status of US 8,945,612?

Inbrija is an FDA-approved small-molecule product, so the relevant abbreviated approval pathway is an ANDA under section 505(j), not a biosimilar application.[2,3]

For a patent to affect an ANDA, it generally must be listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, for the reference product and relevant dosage form. An ANDA applicant may then certify under Paragraph I, II, III or IV depending on the patent’s status and expiration.

The commercial risk associated with US 8,945,612 depends on:

Whether the patent is listed for Inbrija.
The listed expiration date.
Any use code or product-specific listing.
Whether the ANDA product uses the claimed capsule technology.
Whether the applicant files a Paragraph IV certification.
Whether the patent holder brings suit within 45 days.

What would a Paragraph IV challenge involve?

A Paragraph IV challenge could assert:

Invalidity for anticipation or obviousness.
Noninfringement because the product does not use HPMC with titanium dioxide.
Noninfringement because working density falls outside the claimed range.
Failure to meet the levodopa, salt or phospholipid limitations.
Failure to satisfy the comparative emission limitation.
Lack of enablement or indefiniteness relating to powder emission.

If the patent is listed and the sponsor sues within the statutory period, the lawsuit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and litigation developments.[3]

What generic launch scenarios exist?

Scenario 1: Same capsule technology

A generic using HPMC capsules containing titanium dioxide, a low-density levodopa powder and a similar high-drug-load formulation would face the highest risk. Claims 1, 2, 5, 6, 7, 10, 12 and 13 could create overlapping positions.

Scenario 2: Alternative capsule shell

A capsule made from gelatin or another non-HPMC material may avoid the express shell limitation. This is a straightforward design-around, although the alternative shell must still meet inhalation-device compatibility and regulatory requirements.

Scenario 3: HPMC without titanium dioxide

An HPMC capsule free of titanium dioxide would directly target the principal structural limitation. The product would likely avoid literal infringement, assuming titanium dioxide is absent from the shell and not present as an equivalent shell component.

Scenario 4: Different delivery system

A blister, reservoir, cartridge or preloaded inhaler could avoid the capsule limitation. This may require a different device, manufacturing process and FDA product-development strategy.

Scenario 5: Different formulation density

A powder outside 0.02 to 0.1 g/cm³ could avoid claim 1. The design-around must account for doctrine-of-equivalents risk and whether the product remains within the claimed aerodynamic performance ranges.

Which companies are challenging the patent?

No specific Paragraph IV challenger or settlement agreement is established by the supplied claim text. Public ANDA litigation records, FDA listing data and court dockets would control the current challenger analysis.

The principal commercial parties associated with the technology are:

Company	Role
Civitas Therapeutics	Original developer of inhaled levodopa technology
Acorda Therapeutics	Acquired Civitas and commercialized Inbrija
FDA	Approved and regulates Inbrija
Generic manufacturers	Potential ANDA applicants and Paragraph IV challengers

No biosimilar pathway applies. Levodopa is a chemically synthesized small molecule, and a competing product would generally proceed through the generic drug pathway rather than section 351(k).

What manufacturing and IP barriers does the patent create?

The patent can raise manufacturing barriers even where a competitor avoids literal infringement. The relevant development challenges include:

Producing a stable, low-density powder.
Maintaining 2% to 8% water content.
Achieving 50% to 70% fine-particle fraction.
Filling 00 capsules consistently.
Controlling 20 to 50 mg powder fills.
Demonstrating reproducible capsule emptying.
Matching inhaler actuation and aerosol performance.
Preserving powder properties during storage and transport.

These technical requirements can create trade-secret and know-how barriers separate from the patent claims. A competitor that designs around titanium dioxide may still need to replicate comparable delivery performance without using the claimed capsule structure.

How does US 8,945,612 compare with broader inhaled-levodopa patents?

US 8,945,612 is narrower than patents directed broadly to:

Levodopa inhalation therapy.
Treatment of “off” episodes in Parkinson’s disease.
Dry-powder particle engineering.
Inhaler architecture.
Dose-ranging regimens.
Manufacturing methods.
Aerosol delivery performance.

Its commercial value is concentrated in the capsule and powder combination. It may operate as one layer in a broader Inbrija patent estate that includes formulation, device, treatment-method and manufacturing claims.

A freedom-to-operate review should therefore examine the full Civitas/Acorda patent family and continuation patents rather than treating US 8,945,612 as the entire product estate.

Key Takeaways

US 8,945,612 protects a capsule-based inhaled levodopa system, not levodopa inhalation generally.
The core combination is levodopa powder, salt, phospholipid, low working density and an HPMC capsule containing titanium dioxide.
DPPC and sodium chloride are specifically protected in claims 9 and 14.
Claims 6, 7, 12 and 13 target commercial dose and fill-weight ranges.
The comparative powder-emission limitation is central to both infringement and validity analysis.
A gelatin capsule, titanium-dioxide-free HPMC capsule, alternative inhaler or out-of-range powder may provide design-around routes.
Generic competition would proceed through an ANDA and could use a Paragraph IV certification if the patent is listed and unexpired.
Biosimilar analysis is inapplicable because levodopa is a small molecule.
The patent’s term should extend into the early 2030s under the standard 20-year framework, subject to the official patent-term calculation.
The patent should be analyzed with the broader Inbrija formulation, device, method-of-use and manufacturing estate.

FAQs

Does US 8,945,612 cover Inbrija itself?

It can cover the capsule-and-powder configuration used for Inbrija if the marketed product satisfies the limitations in the asserted claim, including HPMC with titanium dioxide, low working density and the claimed levodopa formulation.

Can a generic use the same levodopa dose and avoid the patent?

Yes, potentially. Dose similarity alone does not establish infringement. The generic would need to assess the capsule shell, titanium dioxide, powder density, salt, phospholipid, moisture and emission characteristics.

Is titanium dioxide in the capsule shell required for infringement?

Yes, for literal infringement of claim 1. The claim expressly requires an HPMC shell containing titanium dioxide, together with the other listed limitations.

Does a DPPC formulation automatically infringe claim 14?

No. Claim 14 inherits every limitation of claim 1 and adds sodium chloride and DPPC. DPPC alone is insufficient.

Can FDA approve a generic before the patent expires?

FDA approval may be delayed by listed patent certifications, litigation and any applicable 30-month stay. A successful Paragraph IV challenge, a noninfringement position, a license or a permitted launch date could alter the timing.

References

United States Patent No. 8,945,612. (2015). Capsules for use in inhalation devices. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2018). Inbrija (levodopa) inhalation powder: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	8,945,612	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013342246	⤷ Start Trial
Australia	2013342247	⤷ Start Trial
Australia	2013342248	⤷ Start Trial
Australia	2017279626	⤷ Start Trial
Australia	2018204674	⤷ Start Trial
Australia	2018222983	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,945,612

Which drugs does patent 8,945,612 protect, and when does it expire?

Summary for Patent: 8,945,612